nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—SCN5A—dilated cardiomyopathy	0.372	1	CbGaD
Topiramate—CA6—Furosemide—dilated cardiomyopathy	0.0629	0.139	CbGbCtD
Topiramate—CA5A—Furosemide—dilated cardiomyopathy	0.0629	0.139	CbGbCtD
Topiramate—CA7—Furosemide—dilated cardiomyopathy	0.0548	0.121	CbGbCtD
Topiramate—CA5B—Furosemide—dilated cardiomyopathy	0.0548	0.121	CbGbCtD
Topiramate—CA9—Furosemide—dilated cardiomyopathy	0.047	0.104	CbGbCtD
Topiramate—CA12—Furosemide—dilated cardiomyopathy	0.047	0.104	CbGbCtD
Topiramate—CA1—Furosemide—dilated cardiomyopathy	0.044	0.0972	CbGbCtD
Topiramate—CA4—Furosemide—dilated cardiomyopathy	0.0414	0.0914	CbGbCtD
Topiramate—CA2—Furosemide—dilated cardiomyopathy	0.038	0.084	CbGbCtD
Topiramate—SCN5A—purkinje fiber—dilated cardiomyopathy	0.0167	0.329	CbGeAlD
Topiramate—SCN5A—endocardium—dilated cardiomyopathy	0.0086	0.169	CbGeAlD
Topiramate—CA5B—sinoatrial node—dilated cardiomyopathy	0.00841	0.166	CbGeAlD
Topiramate—SCN5A—sinoatrial node—dilated cardiomyopathy	0.00815	0.161	CbGeAlD
Topiramate—GRIK5—heart—dilated cardiomyopathy	0.00173	0.034	CbGeAlD
Topiramate—GRIK5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00087	0.0179	CbGpPWpGaD
Topiramate—GRIK1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000809	0.0166	CbGpPWpGaD
Topiramate—GRIK3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000809	0.0166	CbGpPWpGaD
Topiramate—GRIA1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—ACTN2—dilated cardiomyopathy	0.000799	0.0164	CbGpPWpGaD
Topiramate—SCN5A—cardiac ventricle—dilated cardiomyopathy	0.000723	0.0143	CbGeAlD
Topiramate—GRIA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000688	0.0141	CbGpPWpGaD
Topiramate—SCN5A—myocardium—dilated cardiomyopathy	0.00068	0.0134	CbGeAlD
Topiramate—SCN5A—Cardiac Progenitor Differentiation—MYH6—dilated cardiomyopathy	0.000672	0.0138	CbGpPWpGaD
Topiramate—GRIK4—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000654	0.0134	CbGpPWpGaD
Topiramate—GRIK5—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000654	0.0134	CbGpPWpGaD
Topiramate—GRIK3—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000608	0.0125	CbGpPWpGaD
Topiramate—GRIK1—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000608	0.0125	CbGpPWpGaD
Topiramate—SCN5A—Cardiac Progenitor Differentiation—TNNI3—dilated cardiomyopathy	0.000599	0.0123	CbGpPWpGaD
Topiramate—SCN1A—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.000594	0.0122	CbGpPWpGaD
Topiramate—GRIK2—heart—dilated cardiomyopathy	0.000585	0.0115	CbGeAlD
Topiramate—GRIA2—Activation of NMDA receptor upon glutamate binding and postsynaptic events—ACTN2—dilated cardiomyopathy	0.000559	0.0115	CbGpPWpGaD
Topiramate—GRIK4—Neuronal System—ABCC9—dilated cardiomyopathy	0.000523	0.0107	CbGpPWpGaD
Topiramate—GRIK5—Neuronal System—ABCC9—dilated cardiomyopathy	0.000523	0.0107	CbGpPWpGaD
Topiramate—GRIA4—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000517	0.0106	CbGpPWpGaD
Topiramate—CA4—cardiac ventricle—dilated cardiomyopathy	0.000515	0.0102	CbGeAlD
Topiramate—SCN5A—Cardiac Progenitor Differentiation—ACTC1—dilated cardiomyopathy	0.000509	0.0105	CbGpPWpGaD
Topiramate—SCN5A—Cardiac Progenitor Differentiation—TNNT2—dilated cardiomyopathy	0.000509	0.0105	CbGpPWpGaD
Topiramate—GRIK5—Neuronal System—ACTN2—dilated cardiomyopathy	0.000501	0.0103	CbGpPWpGaD
Topiramate—GRIK4—Neuronal System—ACTN2—dilated cardiomyopathy	0.000501	0.0103	CbGpPWpGaD
Topiramate—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.0005	0.0103	CbGpPWpGaD
Topiramate—CA5B—heart—dilated cardiomyopathy	0.00049	0.00966	CbGeAlD
Topiramate—GRIK3—Neuronal System—ABCC9—dilated cardiomyopathy	0.000486	0.00999	CbGpPWpGaD
Topiramate—GRIK1—Neuronal System—ABCC9—dilated cardiomyopathy	0.000486	0.00999	CbGpPWpGaD
Topiramate—CA4—myocardium—dilated cardiomyopathy	0.000485	0.00955	CbGeAlD
Topiramate—SCN5A—heart—dilated cardiomyopathy	0.000475	0.00936	CbGeAlD
Topiramate—GRIK3—Neuronal System—ACTN2—dilated cardiomyopathy	0.000466	0.00958	CbGpPWpGaD
Topiramate—GRIK1—Neuronal System—ACTN2—dilated cardiomyopathy	0.000466	0.00958	CbGpPWpGaD
Topiramate—CA1—heart—dilated cardiomyopathy	0.000433	0.00853	CbGeAlD
Topiramate—CA2—cardiac ventricle—dilated cardiomyopathy	0.000427	0.00842	CbGeAlD
Topiramate—CA5B—cardiac atrium—dilated cardiomyopathy	0.000419	0.00826	CbGeAlD
Topiramate—GRIA4—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.000418	0.00859	CbGpPWpGaD
Topiramate—GRIA4—Neuronal System—ABCC9—dilated cardiomyopathy	0.000413	0.00849	CbGpPWpGaD
Topiramate—SCN5A—cardiac atrium—dilated cardiomyopathy	0.000406	0.008	CbGeAlD
Topiramate—CA2—myocardium—dilated cardiomyopathy	0.000402	0.00792	CbGeAlD
Topiramate—GRIA4—Neuronal System—ACTN2—dilated cardiomyopathy	0.000396	0.00814	CbGpPWpGaD
Topiramate—GRIA3—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000376	0.00772	CbGpPWpGaD
Topiramate—Otitis media—Lisinopril—dilated cardiomyopathy	0.000366	0.00483	CcSEcCtD
Topiramate—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.000364	0.0048	CcSEcCtD
Topiramate—Memory impairment—Lisinopril—dilated cardiomyopathy	0.000363	0.00479	CcSEcCtD
Topiramate—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.000352	0.00464	CcSEcCtD
Topiramate—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.000349	0.0046	CcSEcCtD
Topiramate—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.000344	0.00453	CcSEcCtD
Topiramate—Bladder pain—Furosemide—dilated cardiomyopathy	0.000343	0.00453	CcSEcCtD
Topiramate—Urine output increased—Furosemide—dilated cardiomyopathy	0.000343	0.00453	CcSEcCtD
Topiramate—CA4—heart—dilated cardiomyopathy	0.000338	0.00667	CbGeAlD
Topiramate—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000331	0.00437	CcSEcCtD
Topiramate—Mental disability—Furosemide—dilated cardiomyopathy	0.000329	0.00434	CcSEcCtD
Topiramate—Breast pain—Lisinopril—dilated cardiomyopathy	0.000326	0.00431	CcSEcCtD
Topiramate—GRIA1—Amyotrophic lateral sclerosis (ALS)—GPX1—dilated cardiomyopathy	0.000318	0.00653	CbGpPWpGaD
Topiramate—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.000317	0.00418	CcSEcCtD
Topiramate—Viral infection—Lisinopril—dilated cardiomyopathy	0.000315	0.00416	CcSEcCtD
Topiramate—Polyuria—Furosemide—dilated cardiomyopathy	0.000314	0.00414	CcSEcCtD
Topiramate—Arthropathy—Lisinopril—dilated cardiomyopathy	0.000313	0.00413	CcSEcCtD
Topiramate—Alopecia—Spironolactone—dilated cardiomyopathy	0.00031	0.00408	CcSEcCtD
Topiramate—Oliguria—Lisinopril—dilated cardiomyopathy	0.000309	0.00408	CcSEcCtD
Topiramate—Vascular purpura—Furosemide—dilated cardiomyopathy	0.000308	0.00406	CcSEcCtD
Topiramate—Deafness—Furosemide—dilated cardiomyopathy	0.000308	0.00406	CcSEcCtD
Topiramate—Drug interaction—Lisinopril—dilated cardiomyopathy	0.000307	0.00405	CcSEcCtD
Topiramate—GRIA3—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.000304	0.00624	CbGpPWpGaD
Topiramate—GRIA3—Neuronal System—ABCC9—dilated cardiomyopathy	0.0003	0.00617	CbGpPWpGaD
Topiramate—GRIA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000299	0.00615	CbGpPWpGaD
Topiramate—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.000299	0.00395	CcSEcCtD
Topiramate—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000293	0.00387	CcSEcCtD
Topiramate—GRIA1—Amyotrophic lateral sclerosis (ALS)—RAC1—dilated cardiomyopathy	0.000292	0.00599	CbGpPWpGaD
Topiramate—Thirst—Furosemide—dilated cardiomyopathy	0.00029	0.00382	CcSEcCtD
Topiramate—CA4—cardiac atrium—dilated cardiomyopathy	0.000289	0.0057	CbGeAlD
Topiramate—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.000288	0.0038	CcSEcCtD
Topiramate—GRIA3—Neuronal System—ACTN2—dilated cardiomyopathy	0.000288	0.00592	CbGpPWpGaD
Topiramate—Purpura—Furosemide—dilated cardiomyopathy	0.000286	0.00377	CcSEcCtD
Topiramate—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.000285	0.00376	CcSEcCtD
Topiramate—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.000283	0.00373	CcSEcCtD
Topiramate—Lethargy—Furosemide—dilated cardiomyopathy	0.000281	0.00371	CcSEcCtD
Topiramate—CA2—heart—dilated cardiomyopathy	0.000281	0.00553	CbGeAlD
Topiramate—GRIA2—N-cadherin signaling events—GJA1—dilated cardiomyopathy	0.000279	0.00574	CbGpPWpGaD
Topiramate—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.000278	0.00367	CcSEcCtD
Topiramate—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000277	0.00365	CcSEcCtD
Topiramate—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.000277	0.00365	CcSEcCtD
Topiramate—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.000277	0.00365	CcSEcCtD
Topiramate—Malaise—Spironolactone—dilated cardiomyopathy	0.000275	0.00363	CcSEcCtD
Topiramate—Cystitis—Lisinopril—dilated cardiomyopathy	0.000275	0.00363	CcSEcCtD
Topiramate—GRIK2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000274	0.00563	CbGpPWpGaD
Topiramate—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000273	0.0036	CcSEcCtD
Topiramate—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00027	0.00357	CcSEcCtD
Topiramate—Neuropathy—Lisinopril—dilated cardiomyopathy	0.000267	0.00353	CcSEcCtD
Topiramate—Photophobia—Lisinopril—dilated cardiomyopathy	0.000267	0.00353	CcSEcCtD
Topiramate—Irritability—Furosemide—dilated cardiomyopathy	0.000263	0.00347	CcSEcCtD
Topiramate—Urinary retention—Furosemide—dilated cardiomyopathy	0.000262	0.00346	CcSEcCtD
Topiramate—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000258	0.0034	CcSEcCtD
Topiramate—Bladder pain—Lisinopril—dilated cardiomyopathy	0.000258	0.0034	CcSEcCtD
Topiramate—Discomfort—Spironolactone—dilated cardiomyopathy	0.000257	0.00338	CcSEcCtD
Topiramate—Dehydration—Furosemide—dilated cardiomyopathy	0.000256	0.00338	CcSEcCtD
Topiramate—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.000252	0.00332	CcSEcCtD
Topiramate—Confusional state—Spironolactone—dilated cardiomyopathy	0.000251	0.00331	CcSEcCtD
Topiramate—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000251	0.00331	CcSEcCtD
Topiramate—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00025	0.00329	CcSEcCtD
Topiramate—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000248	0.00327	CcSEcCtD
Topiramate—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000244	0.00321	CcSEcCtD
Topiramate—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000243	0.00321	CcSEcCtD
Topiramate—CA2—cardiac atrium—dilated cardiomyopathy	0.00024	0.00473	CbGeAlD
Topiramate—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00024	0.00316	CcSEcCtD
Topiramate—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.000239	0.00315	CcSEcCtD
Topiramate—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.000238	0.00314	CcSEcCtD
Topiramate—Eosinophilia—Furosemide—dilated cardiomyopathy	0.000236	0.00311	CcSEcCtD
Topiramate—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000234	0.00308	CcSEcCtD
Topiramate—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.000233	0.00308	CcSEcCtD
Topiramate—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00023	0.00303	CcSEcCtD
Topiramate—Eczema—Lisinopril—dilated cardiomyopathy	0.00023	0.00303	CcSEcCtD
Topiramate—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.000227	0.00299	CcSEcCtD
Topiramate—GRIA1—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000225	0.00463	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—SCN5A—dilated cardiomyopathy	0.000224	0.00462	CbGpPWpGaD
Topiramate—Libido decreased—Lisinopril—dilated cardiomyopathy	0.000223	0.00294	CcSEcCtD
Topiramate—Somnolence—Spironolactone—dilated cardiomyopathy	0.000221	0.00292	CcSEcCtD
Topiramate—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00022	0.0029	CcSEcCtD
Topiramate—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000217	0.00287	CcSEcCtD
Topiramate—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000215	0.00283	CcSEcCtD
Topiramate—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000215	0.00283	CcSEcCtD
Topiramate—GRIA2—N-cadherin signaling events—RAC1—dilated cardiomyopathy	0.000213	0.00438	CbGpPWpGaD
Topiramate—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000212	0.00279	CcSEcCtD
Topiramate—SCN1A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000211	0.00435	CbGpPWpGaD
Topiramate—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000211	0.00278	CcSEcCtD
Topiramate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000209	0.0043	CbGpPWpGaD
Topiramate—Renal failure—Furosemide—dilated cardiomyopathy	0.000209	0.00275	CcSEcCtD
Topiramate—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000208	0.00274	CcSEcCtD
Topiramate—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.000207	0.00273	CcSEcCtD
Topiramate—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000207	0.00273	CcSEcCtD
Topiramate—Diplopia—Lisinopril—dilated cardiomyopathy	0.000207	0.00273	CcSEcCtD
Topiramate—GRIK2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000206	0.00423	CbGpPWpGaD
Topiramate—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000205	0.00271	CcSEcCtD
Topiramate—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.000205	0.00271	CcSEcCtD
Topiramate—SCN5A—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.000202	0.00415	CbGpPWpGaD
Topiramate—Face oedema—Lisinopril—dilated cardiomyopathy	0.0002	0.00263	CcSEcCtD
Topiramate—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000198	0.00261	CcSEcCtD
Topiramate—GRIK5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000198	0.00407	CbGpPWpGaD
Topiramate—GRIK4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000198	0.00407	CbGpPWpGaD
Topiramate—Urticaria—Spironolactone—dilated cardiomyopathy	0.000198	0.00261	CcSEcCtD
Topiramate—Irritability—Lisinopril—dilated cardiomyopathy	0.000197	0.0026	CcSEcCtD
Topiramate—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000197	0.0026	CcSEcCtD
Topiramate—Ataxia—Lisinopril—dilated cardiomyopathy	0.000194	0.00256	CcSEcCtD
Topiramate—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000194	0.00255	CcSEcCtD
Topiramate—Dehydration—Lisinopril—dilated cardiomyopathy	0.000192	0.00254	CcSEcCtD
Topiramate—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000189	0.00249	CcSEcCtD
Topiramate—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000188	0.00248	CcSEcCtD
Topiramate—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000187	0.00246	CcSEcCtD
Topiramate—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000187	0.00246	CcSEcCtD
Topiramate—GABRA1—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.000187	0.00384	CbGpPWpGaD
Topiramate—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000186	0.00246	CcSEcCtD
Topiramate—GRIA3—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000186	0.00381	CbGpPWpGaD
Topiramate—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000185	0.00244	CcSEcCtD
Topiramate—GRIK3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000184	0.00378	CbGpPWpGaD
Topiramate—GRIK1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000184	0.00378	CbGpPWpGaD
Topiramate—Visual impairment—Furosemide—dilated cardiomyopathy	0.000184	0.00242	CcSEcCtD
Topiramate—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000183	0.00242	CcSEcCtD
Topiramate—Gastritis—Lisinopril—dilated cardiomyopathy	0.000183	0.00241	CcSEcCtD
Topiramate—GRIA1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.000182	0.00374	CbGpPWpGaD
Topiramate—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00018	0.00238	CcSEcCtD
Topiramate—GRIA1—Neuronal System—ABCC9—dilated cardiomyopathy	0.00018	0.0037	CbGpPWpGaD
Topiramate—Asthma—Lisinopril—dilated cardiomyopathy	0.000179	0.00236	CcSEcCtD
Topiramate—Eye disorder—Furosemide—dilated cardiomyopathy	0.000178	0.00235	CcSEcCtD
Topiramate—Tinnitus—Furosemide—dilated cardiomyopathy	0.000178	0.00234	CcSEcCtD
Topiramate—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000177	0.00233	CcSEcCtD
Topiramate—Pruritus—Spironolactone—dilated cardiomyopathy	0.000176	0.00232	CcSEcCtD
Topiramate—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000175	0.00231	CcSEcCtD
Topiramate—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000174	0.0023	CcSEcCtD
Topiramate—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000174	0.0023	CcSEcCtD
Topiramate—Angiopathy—Furosemide—dilated cardiomyopathy	0.000173	0.00228	CcSEcCtD
Topiramate—GRIA1—Neuronal System—ACTN2—dilated cardiomyopathy	0.000172	0.00354	CbGpPWpGaD
Topiramate—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000172	0.00227	CcSEcCtD
Topiramate—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000172	0.00227	CcSEcCtD
Topiramate—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00017	0.00225	CcSEcCtD
Topiramate—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00017	0.00224	CcSEcCtD
Topiramate—GRIA3—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000168	0.00345	CbGpPWpGaD
Topiramate—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000167	0.0022	CcSEcCtD
Topiramate—Dysuria—Lisinopril—dilated cardiomyopathy	0.000167	0.0022	CcSEcCtD
Topiramate—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000166	0.00219	CcSEcCtD
Topiramate—Malnutrition—Furosemide—dilated cardiomyopathy	0.000166	0.00219	CcSEcCtD
Topiramate—Erythema—Furosemide—dilated cardiomyopathy	0.000166	0.00219	CcSEcCtD
Topiramate—Dizziness—Spironolactone—dilated cardiomyopathy	0.000165	0.00217	CcSEcCtD
Topiramate—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000165	0.00217	CcSEcCtD
Topiramate—GRIK2—Neuronal System—ABCC9—dilated cardiomyopathy	0.000164	0.00338	CbGpPWpGaD
Topiramate—Flatulence—Furosemide—dilated cardiomyopathy	0.000164	0.00216	CcSEcCtD
Topiramate—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000163	0.00215	CcSEcCtD
Topiramate—Weight increased—Lisinopril—dilated cardiomyopathy	0.000163	0.00214	CcSEcCtD
Topiramate—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000163	0.00214	CcSEcCtD
Topiramate—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000162	0.00213	CcSEcCtD
Topiramate—GABRB2—Ion channel transport—RYR2—dilated cardiomyopathy	0.000161	0.00332	CbGpPWpGaD
Topiramate—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000161	0.00213	CcSEcCtD
Topiramate—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00016	0.00211	CcSEcCtD
Topiramate—SCN1A—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00016	0.00329	CbGpPWpGaD
Topiramate—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00016	0.0021	CcSEcCtD
Topiramate—Depression—Lisinopril—dilated cardiomyopathy	0.000159	0.0021	CcSEcCtD
Topiramate—Vomiting—Spironolactone—dilated cardiomyopathy	0.000158	0.00209	CcSEcCtD
Topiramate—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000158	0.00208	CcSEcCtD
Topiramate—GRIK2—Neuronal System—ACTN2—dilated cardiomyopathy	0.000158	0.00324	CbGpPWpGaD
Topiramate—GRIA2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000157	0.00324	CbGpPWpGaD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000157	0.00323	CbGpPWpGaD
Topiramate—GABRB2—Ion channel transport—PLN—dilated cardiomyopathy	0.000157	0.00323	CbGpPWpGaD
Topiramate—Rash—Spironolactone—dilated cardiomyopathy	0.000157	0.00207	CcSEcCtD
Topiramate—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000157	0.00207	CcSEcCtD
Topiramate—SCN1A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000157	0.00322	CbGpPWpGaD
Topiramate—Renal failure—Lisinopril—dilated cardiomyopathy	0.000157	0.00207	CcSEcCtD
Topiramate—GRIA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000156	0.00322	CbGpPWpGaD
Topiramate—Vision blurred—Furosemide—dilated cardiomyopathy	0.000156	0.00206	CcSEcCtD
Topiramate—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000156	0.00206	CcSEcCtD
Topiramate—Headache—Spironolactone—dilated cardiomyopathy	0.000156	0.00206	CcSEcCtD
Topiramate—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000155	0.00204	CcSEcCtD
Topiramate—Anaemia—Furosemide—dilated cardiomyopathy	0.000153	0.00202	CcSEcCtD
Topiramate—Agitation—Furosemide—dilated cardiomyopathy	0.000152	0.00201	CcSEcCtD
Topiramate—Haematuria—Lisinopril—dilated cardiomyopathy	0.000152	0.002	CcSEcCtD
Topiramate—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00015	0.00198	CcSEcCtD
Topiramate—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000149	0.00197	CcSEcCtD
Topiramate—Vertigo—Furosemide—dilated cardiomyopathy	0.000149	0.00197	CcSEcCtD
Topiramate—GRIK4—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000149	0.00306	CbGpPWpGaD
Topiramate—GRIK5—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000149	0.00306	CbGpPWpGaD
Topiramate—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000149	0.00196	CcSEcCtD
Topiramate—SCN5A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000149	0.00306	CbGpPWpGaD
Topiramate—Leukopenia—Furosemide—dilated cardiomyopathy	0.000149	0.00196	CcSEcCtD
Topiramate—Nausea—Spironolactone—dilated cardiomyopathy	0.000148	0.00195	CcSEcCtD
Topiramate—GABRG2—Ion channel transport—RYR2—dilated cardiomyopathy	0.000148	0.00303	CbGpPWpGaD
Topiramate—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000146	0.00192	CcSEcCtD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000144	0.00296	CbGpPWpGaD
Topiramate—GABRG2—Ion channel transport—PLN—dilated cardiomyopathy	0.000144	0.00295	CbGpPWpGaD
Topiramate—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000143	0.00189	CcSEcCtD
Topiramate—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000143	0.00189	CcSEcCtD
Topiramate—Hallucination—Lisinopril—dilated cardiomyopathy	0.000142	0.00188	CcSEcCtD
Topiramate—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000142	0.00187	CcSEcCtD
Topiramate—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000141	0.00186	CcSEcCtD
Topiramate—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000141	0.00186	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00014	0.00185	CcSEcCtD
Topiramate—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00014	0.00185	CcSEcCtD
Topiramate—GRIK3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000138	0.00284	CbGpPWpGaD
Topiramate—GRIK1—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000138	0.00284	CbGpPWpGaD
Topiramate—Dry mouth—Furosemide—dilated cardiomyopathy	0.000138	0.00182	CcSEcCtD
Topiramate—Confusional state—Furosemide—dilated cardiomyopathy	0.000137	0.0018	CcSEcCtD
Topiramate—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000135	0.00178	CcSEcCtD
Topiramate—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000133	0.00176	CcSEcCtD
Topiramate—Shock—Furosemide—dilated cardiomyopathy	0.000133	0.00176	CcSEcCtD
Topiramate—GABRA1—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.000133	0.00273	CbGpPWpGaD
Topiramate—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000133	0.00175	CcSEcCtD
Topiramate—Flushing—Lisinopril—dilated cardiomyopathy	0.000133	0.00175	CcSEcCtD
Topiramate—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000133	0.00175	CcSEcCtD
Topiramate—Skin disorder—Furosemide—dilated cardiomyopathy	0.000132	0.00174	CcSEcCtD
Topiramate—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000131	0.00173	CcSEcCtD
Topiramate—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00013	0.00171	CcSEcCtD
Topiramate—Anorexia—Furosemide—dilated cardiomyopathy	0.000129	0.0017	CcSEcCtD
Topiramate—GABRA1—Ion channel transport—RYR2—dilated cardiomyopathy	0.000129	0.00265	CbGpPWpGaD
Topiramate—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000129	0.0017	CcSEcCtD
Topiramate—Chills—Lisinopril—dilated cardiomyopathy	0.000128	0.00169	CcSEcCtD
Topiramate—GRIA2—Activation of NMDA receptor upon glutamate binding and postsynaptic events—RAF1—dilated cardiomyopathy	0.000127	0.00262	CbGpPWpGaD
Topiramate—Hypotension—Furosemide—dilated cardiomyopathy	0.000127	0.00167	CcSEcCtD
Topiramate—Alopecia—Lisinopril—dilated cardiomyopathy	0.000126	0.00167	CcSEcCtD
Topiramate—GRIA1—Amyotrophic lateral sclerosis (ALS)—TNF—dilated cardiomyopathy	0.000126	0.0026	CbGpPWpGaD
Topiramate—SCN1A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000126	0.00259	CbGpPWpGaD
Topiramate—GRIA2—Neuronal System—ABCC9—dilated cardiomyopathy	0.000126	0.00259	CbGpPWpGaD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.000126	0.00258	CbGpPWpGaD
Topiramate—GABRA1—Ion channel transport—PLN—dilated cardiomyopathy	0.000125	0.00258	CbGpPWpGaD
Topiramate—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000125	0.00165	CcSEcCtD
Topiramate—Erythema—Lisinopril—dilated cardiomyopathy	0.000125	0.00164	CcSEcCtD
Topiramate—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000125	0.00164	CcSEcCtD
Topiramate—CYP2C19—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000124	0.00255	CbGpPWpGaD
Topiramate—Flatulence—Lisinopril—dilated cardiomyopathy	0.000123	0.00162	CcSEcCtD
Topiramate—Tension—Lisinopril—dilated cardiomyopathy	0.000122	0.00161	CcSEcCtD
Topiramate—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000122	0.00161	CcSEcCtD
Topiramate—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000122	0.0016	CcSEcCtD
Topiramate—Nervousness—Lisinopril—dilated cardiomyopathy	0.000121	0.0016	CcSEcCtD
Topiramate—GRIA2—Neuronal System—ACTN2—dilated cardiomyopathy	0.000121	0.00248	CbGpPWpGaD
Topiramate—Back pain—Lisinopril—dilated cardiomyopathy	0.00012	0.00159	CcSEcCtD
Topiramate—Somnolence—Furosemide—dilated cardiomyopathy	0.00012	0.00159	CcSEcCtD
Topiramate—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00012	0.00158	CcSEcCtD
Topiramate—GABRB2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000118	0.00243	CbGpPWpGaD
Topiramate—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000118	0.00155	CcSEcCtD
Topiramate—GRIA4—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000118	0.00242	CbGpPWpGaD
Topiramate—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000117	0.00155	CcSEcCtD
Topiramate—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000117	0.00154	CcSEcCtD
Topiramate—Fatigue—Furosemide—dilated cardiomyopathy	0.000117	0.00154	CcSEcCtD
Topiramate—Tremor—Lisinopril—dilated cardiomyopathy	0.000117	0.00154	CcSEcCtD
Topiramate—Constipation—Furosemide—dilated cardiomyopathy	0.000116	0.00153	CcSEcCtD
Topiramate—Pain—Furosemide—dilated cardiomyopathy	0.000116	0.00153	CcSEcCtD
Topiramate—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000116	0.00152	CcSEcCtD
Topiramate—Anaemia—Lisinopril—dilated cardiomyopathy	0.000115	0.00152	CcSEcCtD
Topiramate—GRIK4—Neuronal System—RAF1—dilated cardiomyopathy	0.000114	0.00234	CbGpPWpGaD
Topiramate—GRIK5—Neuronal System—RAF1—dilated cardiomyopathy	0.000114	0.00234	CbGpPWpGaD
Topiramate—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000114	0.00234	CbGpPWpGaD
Topiramate—Malaise—Lisinopril—dilated cardiomyopathy	0.000112	0.00148	CcSEcCtD
Topiramate—Vertigo—Lisinopril—dilated cardiomyopathy	0.000112	0.00148	CcSEcCtD
Topiramate—Syncope—Lisinopril—dilated cardiomyopathy	0.000112	0.00147	CcSEcCtD
Topiramate—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000112	0.00147	CcSEcCtD
Topiramate—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000111	0.00147	CcSEcCtD
Topiramate—GRIA3—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000111	0.00229	CbGpPWpGaD
Topiramate—GRIA1—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000111	0.00229	CbGpPWpGaD
Topiramate—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000111	0.00146	CcSEcCtD
Topiramate—SCN5A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.00011	0.00226	CbGpPWpGaD
Topiramate—Palpitations—Lisinopril—dilated cardiomyopathy	0.00011	0.00145	CcSEcCtD
Topiramate—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000109	0.00144	CcSEcCtD
Topiramate—Cough—Lisinopril—dilated cardiomyopathy	0.000109	0.00143	CcSEcCtD
Topiramate—GABRG2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000108	0.00222	CbGpPWpGaD
Topiramate—Urticaria—Furosemide—dilated cardiomyopathy	0.000108	0.00142	CcSEcCtD
Topiramate—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000107	0.00141	CcSEcCtD
Topiramate—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000107	0.00141	CcSEcCtD
Topiramate—Chest pain—Lisinopril—dilated cardiomyopathy	0.000106	0.0014	CcSEcCtD
Topiramate—Myalgia—Lisinopril—dilated cardiomyopathy	0.000106	0.0014	CcSEcCtD
Topiramate—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000106	0.0014	CcSEcCtD
Topiramate—GRIK1—Neuronal System—RAF1—dilated cardiomyopathy	0.000106	0.00218	CbGpPWpGaD
Topiramate—GRIK3—Neuronal System—RAF1—dilated cardiomyopathy	0.000106	0.00218	CbGpPWpGaD
Topiramate—Anxiety—Lisinopril—dilated cardiomyopathy	0.000106	0.00139	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000105	0.00139	CcSEcCtD
Topiramate—Discomfort—Lisinopril—dilated cardiomyopathy	0.000105	0.00138	CcSEcCtD
Topiramate—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000104	0.00137	CcSEcCtD
Topiramate—Confusional state—Lisinopril—dilated cardiomyopathy	0.000102	0.00135	CcSEcCtD
Topiramate—Oedema—Lisinopril—dilated cardiomyopathy	0.000102	0.00134	CcSEcCtD
Topiramate—Infection—Lisinopril—dilated cardiomyopathy	0.000101	0.00133	CcSEcCtD
Topiramate—GRIA1—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.0001	0.00206	CbGpPWpGaD
Topiramate—Shock—Lisinopril—dilated cardiomyopathy	0.0001	0.00132	CcSEcCtD
Topiramate—Hypersensitivity—Furosemide—dilated cardiomyopathy	9.98e-05	0.00132	CcSEcCtD
Topiramate—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	9.95e-05	0.00131	CcSEcCtD
Topiramate—Tachycardia—Lisinopril—dilated cardiomyopathy	9.92e-05	0.00131	CcSEcCtD
Topiramate—Skin disorder—Lisinopril—dilated cardiomyopathy	9.87e-05	0.0013	CcSEcCtD
Topiramate—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	9.82e-05	0.0013	CcSEcCtD
Topiramate—CA6—Metabolism—ANKRD1—dilated cardiomyopathy	9.72e-05	0.002	CbGpPWpGaD
Topiramate—CA5A—Metabolism—ANKRD1—dilated cardiomyopathy	9.72e-05	0.002	CbGpPWpGaD
Topiramate—Asthenia—Furosemide—dilated cardiomyopathy	9.72e-05	0.00128	CcSEcCtD
Topiramate—Anorexia—Lisinopril—dilated cardiomyopathy	9.69e-05	0.00128	CcSEcCtD
Topiramate—Pruritus—Furosemide—dilated cardiomyopathy	9.58e-05	0.00126	CcSEcCtD
Topiramate—Hypotension—Lisinopril—dilated cardiomyopathy	9.5e-05	0.00125	CcSEcCtD
Topiramate—SCN1A—Axon guidance—PSEN2—dilated cardiomyopathy	9.46e-05	0.00195	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	9.45e-05	0.00194	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—ABCC9—dilated cardiomyopathy	9.45e-05	0.00194	CbGpPWpGaD
Topiramate—Diarrhoea—Furosemide—dilated cardiomyopathy	9.27e-05	0.00122	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	9.26e-05	0.00122	CcSEcCtD
Topiramate—Insomnia—Lisinopril—dilated cardiomyopathy	9.19e-05	0.00121	CcSEcCtD
Topiramate—CA5A—Metabolism—TAZ—dilated cardiomyopathy	9.14e-05	0.00188	CbGpPWpGaD
Topiramate—CA6—Metabolism—TAZ—dilated cardiomyopathy	9.14e-05	0.00188	CbGpPWpGaD
Topiramate—Paraesthesia—Lisinopril—dilated cardiomyopathy	9.12e-05	0.0012	CcSEcCtD
Topiramate—CA5B—Metabolism—ANKRD1—dilated cardiomyopathy	9.07e-05	0.00187	CbGpPWpGaD
Topiramate—CA7—Metabolism—ANKRD1—dilated cardiomyopathy	9.07e-05	0.00187	CbGpPWpGaD
Topiramate—Dyspnoea—Lisinopril—dilated cardiomyopathy	9.06e-05	0.00119	CcSEcCtD
Topiramate—GABRB2—Neuronal System—ACTN2—dilated cardiomyopathy	9.06e-05	0.00186	CbGpPWpGaD
Topiramate—Somnolence—Lisinopril—dilated cardiomyopathy	9.03e-05	0.00119	CcSEcCtD
Topiramate—GRIA4—Neuronal System—RAF1—dilated cardiomyopathy	9.01e-05	0.00185	CbGpPWpGaD
Topiramate—Dizziness—Furosemide—dilated cardiomyopathy	8.96e-05	0.00118	CcSEcCtD
Topiramate—Dyspepsia—Lisinopril—dilated cardiomyopathy	8.94e-05	0.00118	CcSEcCtD
Topiramate—SCN5A—L1CAM interactions—RAC1—dilated cardiomyopathy	8.85e-05	0.00182	CbGpPWpGaD
Topiramate—Decreased appetite—Lisinopril—dilated cardiomyopathy	8.83e-05	0.00117	CcSEcCtD
Topiramate—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	8.77e-05	0.00116	CcSEcCtD
Topiramate—Fatigue—Lisinopril—dilated cardiomyopathy	8.76e-05	0.00116	CcSEcCtD
Topiramate—Pain—Lisinopril—dilated cardiomyopathy	8.69e-05	0.00115	CcSEcCtD
Topiramate—Constipation—Lisinopril—dilated cardiomyopathy	8.69e-05	0.00115	CcSEcCtD
Topiramate—GABRG2—Neuronal System—ABCC9—dilated cardiomyopathy	8.64e-05	0.00178	CbGpPWpGaD
Topiramate—Vomiting—Furosemide—dilated cardiomyopathy	8.61e-05	0.00114	CcSEcCtD
Topiramate—GRIA3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	8.55e-05	0.00176	CbGpPWpGaD
Topiramate—Rash—Furosemide—dilated cardiomyopathy	8.54e-05	0.00113	CcSEcCtD
Topiramate—CA7—Metabolism—TAZ—dilated cardiomyopathy	8.53e-05	0.00175	CbGpPWpGaD
Topiramate—CA5B—Metabolism—TAZ—dilated cardiomyopathy	8.53e-05	0.00175	CbGpPWpGaD
Topiramate—Dermatitis—Furosemide—dilated cardiomyopathy	8.53e-05	0.00113	CcSEcCtD
Topiramate—Headache—Furosemide—dilated cardiomyopathy	8.48e-05	0.00112	CcSEcCtD
Topiramate—CA12—Metabolism—ANKRD1—dilated cardiomyopathy	8.41e-05	0.00173	CbGpPWpGaD
Topiramate—Feeling abnormal—Lisinopril—dilated cardiomyopathy	8.37e-05	0.0011	CcSEcCtD
Topiramate—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	8.31e-05	0.0011	CcSEcCtD
Topiramate—GABRG2—Neuronal System—ACTN2—dilated cardiomyopathy	8.28e-05	0.0017	CbGpPWpGaD
Topiramate—CA5A—Metabolism—SDHA—dilated cardiomyopathy	8.26e-05	0.0017	CbGpPWpGaD
Topiramate—CA6—Metabolism—SDHA—dilated cardiomyopathy	8.26e-05	0.0017	CbGpPWpGaD
Topiramate—Urticaria—Lisinopril—dilated cardiomyopathy	8.07e-05	0.00106	CcSEcCtD
Topiramate—Nausea—Furosemide—dilated cardiomyopathy	8.04e-05	0.00106	CcSEcCtD
Topiramate—Body temperature increased—Lisinopril—dilated cardiomyopathy	8.03e-05	0.00106	CcSEcCtD
Topiramate—Abdominal pain—Lisinopril—dilated cardiomyopathy	8.03e-05	0.00106	CcSEcCtD
Topiramate—CA12—Metabolism—TAZ—dilated cardiomyopathy	7.9e-05	0.00163	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	7.88e-05	0.00162	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	7.77e-05	0.0016	CbGpPWpGaD
Topiramate—CA5B—Metabolism—SDHA—dilated cardiomyopathy	7.72e-05	0.00159	CbGpPWpGaD
Topiramate—CA7—Metabolism—SDHA—dilated cardiomyopathy	7.72e-05	0.00159	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—ABCC9—dilated cardiomyopathy	7.55e-05	0.00155	CbGpPWpGaD
Topiramate—Hypersensitivity—Lisinopril—dilated cardiomyopathy	7.49e-05	0.000987	CcSEcCtD
Topiramate—Asthenia—Lisinopril—dilated cardiomyopathy	7.29e-05	0.000962	CcSEcCtD
Topiramate—GABRA1—Neuronal System—ACTN2—dilated cardiomyopathy	7.24e-05	0.00149	CbGpPWpGaD
Topiramate—Pruritus—Lisinopril—dilated cardiomyopathy	7.19e-05	0.000948	CcSEcCtD
Topiramate—CA12—Metabolism—SDHA—dilated cardiomyopathy	7.15e-05	0.00147	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—RAC1—dilated cardiomyopathy	7.02e-05	0.00144	CbGpPWpGaD
Topiramate—Diarrhoea—Lisinopril—dilated cardiomyopathy	6.95e-05	0.000917	CcSEcCtD
Topiramate—SCN5A—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	6.83e-05	0.0014	CbGpPWpGaD
Topiramate—GRIA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	6.81e-05	0.0014	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—PSEN2—dilated cardiomyopathy	6.75e-05	0.00139	CbGpPWpGaD
Topiramate—Dizziness—Lisinopril—dilated cardiomyopathy	6.72e-05	0.000886	CcSEcCtD
Topiramate—CA4—Metabolism—ANKRD1—dilated cardiomyopathy	6.7e-05	0.00138	CbGpPWpGaD
Topiramate—GRIA1—BDNF signaling pathway—RAF1—dilated cardiomyopathy	6.66e-05	0.00137	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—PSEN2—dilated cardiomyopathy	6.65e-05	0.00137	CbGpPWpGaD
Topiramate—GRIA3—Neuronal System—RAF1—dilated cardiomyopathy	6.55e-05	0.00135	CbGpPWpGaD
Topiramate—Vomiting—Lisinopril—dilated cardiomyopathy	6.46e-05	0.000852	CcSEcCtD
Topiramate—CA2—Metabolism—ANKRD1—dilated cardiomyopathy	6.43e-05	0.00132	CbGpPWpGaD
Topiramate—Rash—Lisinopril—dilated cardiomyopathy	6.41e-05	0.000845	CcSEcCtD
Topiramate—Dermatitis—Lisinopril—dilated cardiomyopathy	6.4e-05	0.000844	CcSEcCtD
Topiramate—Headache—Lisinopril—dilated cardiomyopathy	6.37e-05	0.00084	CcSEcCtD
Topiramate—CA4—Metabolism—TAZ—dilated cardiomyopathy	6.3e-05	0.0013	CbGpPWpGaD
Topiramate—GRIK2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	6.23e-05	0.00128	CbGpPWpGaD
Topiramate—CA1—Metabolism—ANKRD1—dilated cardiomyopathy	6.16e-05	0.00127	CbGpPWpGaD
Topiramate—CA2—Metabolism—TAZ—dilated cardiomyopathy	6.04e-05	0.00124	CbGpPWpGaD
Topiramate—Nausea—Lisinopril—dilated cardiomyopathy	6.04e-05	0.000796	CcSEcCtD
Topiramate—SCN1A—Axon guidance—ITGB1—dilated cardiomyopathy	5.92e-05	0.00122	CbGpPWpGaD
Topiramate—CA1—Metabolism—TAZ—dilated cardiomyopathy	5.79e-05	0.00119	CbGpPWpGaD
Topiramate—SCN1A—L1CAM interactions—EGFR—dilated cardiomyopathy	5.73e-05	0.00118	CbGpPWpGaD
Topiramate—CA4—Metabolism—SDHA—dilated cardiomyopathy	5.7e-05	0.00117	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	5.62e-05	0.00115	CbGpPWpGaD
Topiramate—CYP2C19—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	5.5e-05	0.00113	CbGpPWpGaD
Topiramate—CA2—Metabolism—SDHA—dilated cardiomyopathy	5.47e-05	0.00112	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	5.46e-05	0.00112	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	5.46e-05	0.00112	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—SOD2—dilated cardiomyopathy	5.44e-05	0.00112	CbGpPWpGaD
Topiramate—CA9—Metabolism—ANKRD1—dilated cardiomyopathy	5.42e-05	0.00111	CbGpPWpGaD
Topiramate—CA1—Metabolism—SDHA—dilated cardiomyopathy	5.24e-05	0.00108	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—GPX1—dilated cardiomyopathy	5.19e-05	0.00107	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	5.19e-05	0.00107	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	5.14e-05	0.00106	CbGpPWpGaD
Topiramate—GRIA1—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	5.12e-05	0.00105	CbGpPWpGaD
Topiramate—CA9—Metabolism—TAZ—dilated cardiomyopathy	5.09e-05	0.00105	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.08e-05	0.00104	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	5e-05	0.00103	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	5e-05	0.00103	CbGpPWpGaD
Topiramate—GRIA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	4.76e-05	0.000979	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—RAC1—dilated cardiomyopathy	4.76e-05	0.000978	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—PSEN2—dilated cardiomyopathy	4.75e-05	0.000976	CbGpPWpGaD
Topiramate—GRIK2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	4.68e-05	0.000963	CbGpPWpGaD
Topiramate—GRIA2—BDNF signaling pathway—RAF1—dilated cardiomyopathy	4.66e-05	0.000957	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	4.65e-05	0.000955	CbGpPWpGaD
Topiramate—CA9—Metabolism—SDHA—dilated cardiomyopathy	4.61e-05	0.000947	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	4.5e-05	0.000925	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	4.49e-05	0.000923	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	4.37e-05	0.000898	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	4.37e-05	0.000898	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—ITGB1—dilated cardiomyopathy	4.22e-05	0.000869	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—ITGB1—dilated cardiomyopathy	4.16e-05	0.000856	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	4.06e-05	0.000835	CbGpPWpGaD
Topiramate—SCN5A—L1CAM interactions—EGFR—dilated cardiomyopathy	4.03e-05	0.000828	CbGpPWpGaD
Topiramate—GRIA1—Neuronal System—RAF1—dilated cardiomyopathy	3.92e-05	0.000806	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—CD36—dilated cardiomyopathy	3.6e-05	0.000741	CbGpPWpGaD
Topiramate—GRIK2—Neuronal System—RAF1—dilated cardiomyopathy	3.59e-05	0.000738	CbGpPWpGaD
Topiramate—GRIA2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	3.58e-05	0.000736	CbGpPWpGaD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	3.58e-05	0.000735	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	3.41e-05	0.0007	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—RAC1—dilated cardiomyopathy	3.4e-05	0.000698	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—RAC1—dilated cardiomyopathy	3.35e-05	0.000688	CbGpPWpGaD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	3.27e-05	0.000673	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	3.2e-05	0.000658	CbGpPWpGaD
Topiramate—GABRB2—Ion channel transport—RAF1—dilated cardiomyopathy	3.18e-05	0.000654	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—RAF1—dilated cardiomyopathy	3.16e-05	0.000649	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—ITGB1—dilated cardiomyopathy	2.97e-05	0.000611	CbGpPWpGaD
Topiramate—GABRG2—Ion channel transport—RAF1—dilated cardiomyopathy	2.91e-05	0.000599	CbGpPWpGaD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	2.86e-05	0.000588	CbGpPWpGaD
Topiramate—GRIA2—Neuronal System—RAF1—dilated cardiomyopathy	2.74e-05	0.000564	CbGpPWpGaD
Topiramate—GABRB2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	2.69e-05	0.000553	CbGpPWpGaD
Topiramate—SCN5A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	2.6e-05	0.000534	CbGpPWpGaD
Topiramate—GABRA1—Ion channel transport—RAF1—dilated cardiomyopathy	2.54e-05	0.000523	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—CD36—dilated cardiomyopathy	2.53e-05	0.000521	CbGpPWpGaD
Topiramate—GABRG2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	2.46e-05	0.000506	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—RAC1—dilated cardiomyopathy	2.39e-05	0.000491	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—RAF1—dilated cardiomyopathy	2.25e-05	0.000463	CbGpPWpGaD
Topiramate—CA6—Metabolism—GPX1—dilated cardiomyopathy	2.25e-05	0.000462	CbGpPWpGaD
Topiramate—CA5A—Metabolism—GPX1—dilated cardiomyopathy	2.25e-05	0.000462	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—RAF1—dilated cardiomyopathy	2.22e-05	0.000456	CbGpPWpGaD
Topiramate—CA6—Metabolism—CD36—dilated cardiomyopathy	2.19e-05	0.00045	CbGpPWpGaD
Topiramate—CA5A—Metabolism—CD36—dilated cardiomyopathy	2.19e-05	0.00045	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—EGFR—dilated cardiomyopathy	2.16e-05	0.000445	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	2.15e-05	0.000442	CbGpPWpGaD
Topiramate—CA5B—Metabolism—GPX1—dilated cardiomyopathy	2.1e-05	0.000431	CbGpPWpGaD
Topiramate—CA7—Metabolism—GPX1—dilated cardiomyopathy	2.1e-05	0.000431	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—RAF1—dilated cardiomyopathy	2.06e-05	0.000424	CbGpPWpGaD
Topiramate—CA5B—Metabolism—CD36—dilated cardiomyopathy	2.04e-05	0.00042	CbGpPWpGaD
Topiramate—CA7—Metabolism—CD36—dilated cardiomyopathy	2.04e-05	0.00042	CbGpPWpGaD
Topiramate—CA5A—Metabolism—AGT—dilated cardiomyopathy	1.97e-05	0.000405	CbGpPWpGaD
Topiramate—CA6—Metabolism—AGT—dilated cardiomyopathy	1.97e-05	0.000405	CbGpPWpGaD
Topiramate—CA12—Metabolism—GPX1—dilated cardiomyopathy	1.94e-05	0.000399	CbGpPWpGaD
Topiramate—CA12—Metabolism—CD36—dilated cardiomyopathy	1.89e-05	0.000389	CbGpPWpGaD
Topiramate—GABRG2—Neuronal System—RAF1—dilated cardiomyopathy	1.88e-05	0.000387	CbGpPWpGaD
Topiramate—CA5B—Metabolism—AGT—dilated cardiomyopathy	1.84e-05	0.000378	CbGpPWpGaD
Topiramate—CA7—Metabolism—AGT—dilated cardiomyopathy	1.84e-05	0.000378	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	1.71e-05	0.000352	CbGpPWpGaD
Topiramate—CA12—Metabolism—AGT—dilated cardiomyopathy	1.7e-05	0.00035	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—RAF1—dilated cardiomyopathy	1.65e-05	0.000339	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—RAF1—dilated cardiomyopathy	1.58e-05	0.000325	CbGpPWpGaD
Topiramate—CA4—Metabolism—GPX1—dilated cardiomyopathy	1.55e-05	0.000318	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—EGFR—dilated cardiomyopathy	1.54e-05	0.000317	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—EGFR—dilated cardiomyopathy	1.52e-05	0.000313	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	1.52e-05	0.000312	CbGpPWpGaD
Topiramate—CA4—Metabolism—CD36—dilated cardiomyopathy	1.51e-05	0.00031	CbGpPWpGaD
Topiramate—CA2—Metabolism—GPX1—dilated cardiomyopathy	1.48e-05	0.000305	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—TNF—dilated cardiomyopathy	1.47e-05	0.000302	CbGpPWpGaD
Topiramate—CA2—Metabolism—CD36—dilated cardiomyopathy	1.45e-05	0.000297	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	1.43e-05	0.000293	CbGpPWpGaD
Topiramate—CA1—Metabolism—GPX1—dilated cardiomyopathy	1.42e-05	0.000293	CbGpPWpGaD
Topiramate—CA1—Metabolism—CD36—dilated cardiomyopathy	1.39e-05	0.000285	CbGpPWpGaD
Topiramate—CA4—Metabolism—AGT—dilated cardiomyopathy	1.36e-05	0.000279	CbGpPWpGaD
Topiramate—CA2—Metabolism—AGT—dilated cardiomyopathy	1.3e-05	0.000268	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	1.29e-05	0.000265	CbGpPWpGaD
Topiramate—CA9—Metabolism—GPX1—dilated cardiomyopathy	1.25e-05	0.000257	CbGpPWpGaD
Topiramate—CA1—Metabolism—AGT—dilated cardiomyopathy	1.25e-05	0.000257	CbGpPWpGaD
Topiramate—CA9—Metabolism—CD36—dilated cardiomyopathy	1.22e-05	0.000251	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.11e-05	0.000228	CbGpPWpGaD
Topiramate—CA9—Metabolism—AGT—dilated cardiomyopathy	1.1e-05	0.000226	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—EGFR—dilated cardiomyopathy	1.09e-05	0.000223	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—TNF—dilated cardiomyopathy	1.03e-05	0.000213	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.01e-05	0.000208	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	9.12e-06	0.000187	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	8.86e-06	0.000182	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	8.57e-06	0.000176	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	7.87e-06	0.000162	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	7.75e-06	0.000159	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	7.66e-06	0.000157	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.9e-06	0.000142	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	3.5e-06	7.2e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	3.41e-06	7.01e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	3.07e-06	6.32e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.11e-06	4.33e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.05e-06	4.22e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.85e-06	3.8e-05	CbGpPWpGaD
